HOME > LATEST
LATEST
-
BUSINESS Takeda on Course to Stable Growth as Late-Stage Assets Near Market
May 9, 2025
-
BUSINESS Lilly Japan Scores Double-Digit Growth for 2nd Year as Mounjaro Delivers
May 9, 2025
-
BUSINESS Ono’s Profits Slide Over 60% as Deciphera Buyout Costs Swell
May 9, 2025
-
REGULATORY Ruling Bloc, Ishin Reach No Deal on Coverage of OTC-Like Drugs
May 8, 2025
-
ORGANIZATION PhRMA Questions Utility of Proposed Expert Committee for Patent Linkage
May 8, 2025
-
BUSINESS Kyowa Kirin Announces Another Buyout Package; Job Cut Target Not Set
May 8, 2025
-
BUSINESS Pfizer Seeks Wider Label for PARP Inhibitor Talzenna in Japan
May 8, 2025
-
BUSINESS Cheplapharm to Take Over Japan MA for Fuji Pharma’s Vesanoid
May 8, 2025
-
BUSINESS Medipal/JCR’s MPS IIIB Therapy Snags Orphan Tag in US
May 8, 2025
-
BUSINESS Enhertu Hits Main Goal in Neoadjuvant Trial for Breast Cancer
May 8, 2025
-
BUSINESS Shionogi to Buy Torii in 160 Billion Yen Deal, JT Pulls Plug on Pharma Biz
May 8, 2025
-
ORGANIZATION Generic Rate in Japan Reaches 89.3% at 2024-End: Payer
May 8, 2025
-
COMMENTARY New Grad Hires for Sales Reps Up after 5 Years of Decrease: FY2025 Survey
May 8, 2025
-
REGULATORY MHLW to Set Up Special Panel for High-Cost Medical Expense Benefit Program
May 7, 2025
-
BUSINESS Leqembi’s FY2024 Sales at 44.3 Billion Yen: Eisai
May 7, 2025
-
BUSINESS Lilly’s Eczema Drug Ebglyss Now Available for Self-Injection
May 7, 2025
-
BUSINESS Kyowa Kirin’s Q1 Profits Down Over 50% on Higher R&D Spending
May 7, 2025
-
BUSINESS Satsuma’s Nasal Powder Drug for Migraine Approved in US
May 7, 2025
-
BUSINESS Otsuka's Profit Might Drop by Billions if US Imposes 25% Tariff
May 7, 2025
-
REGULATORY AMED to Strengthen Coordination Between Projects: New President
May 7, 2025
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…